Blockchain Registration Transaction Record

Soligenix's HyBryte™ Shows 75% Response Rate in Skin Cancer Trial

Soligenix announces positive results for HyBryte™ skin cancer treatment, with 75% of patients showing improvement in CTCL after 18 weeks. The treatment offers a faster and safer alternative, potentially revolutionizing the standard of care for this rare disease.

Soligenix's HyBryte™ Shows 75% Response Rate in Skin Cancer Trial

This news matters as Soligenix's innovative skin cancer treatment has the potential to offer a faster, safer, and more effective solution for CTCL patients, addressing a critical unmet need in the market. With promising clinical data and government funding support, HyBryte™ could significantly impact the lives of those suffering from this chronic, incurable disease.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x19903c02008cf058070d2f9cf0fefb6fb0a11eeea882df3d53b2a6cf229b92ff
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintknobrkBp-51dbab56a69ad8866dd6266f95325b98